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Crohn’s disease (CD) is a chronic inflammatory disease in which cytokines play a pivotal
role in the induction and maintenance of inflammation. Innate cytokine production is geneti-
cally determined and varies largely between individuals; this might impact the severity of
inflammation. We aimed to assess whether ex-vivo endotoxin-stimulated levels of cytokines
could be associated with disease phenotype.
Methods
Patients with quiescent CD (Harvey-Bradshaw Index 4 and negative inflammation mark-
ers) who were not using immunomodulating drugs or biologicals were eligible. Historical dis-
ease characteristics (localization, behavior, number of bowel resections, drug history, extra-
intestinal symptoms) were extracted from medical records. We measured cytokine levels
(tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and IL-10) in supernatants of lipo-
polysaccharide (LPS) -stimulated whole blood cultures and correlated these with disease
characteristics and age- and sex-matched healthy controls. In addition, we analyzed
whether single nucleotide polymorphisms (SNPs) in the promoter region of the TNF-α gene
were related to TNF-α levels.
Results
We included 75 patients with CD and 24 healthy controls. Six patients were excluded
because of increased inflammation markers resulting in a total of 69 patients. The mean
age (SD) of patients with CD was 51.2 (12.3) years with a mean (SD) disease duration of
24.1 (11.5) years. Disease localization, peri-anal involvement and behavior were not related
to LPS-stimulated TNF-α, IL-1β, IL-6 or IL-10 levels. In addition, combination of localization
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with behavior to differentiate mild from severe disease type showed no significant differ-
ences. TNF-α levels were higher in patients with CD (428 pg/ml IQR [267-468]) compared
to healthy controls (459 pg/ml IQR [364-570], p=0.02). We found no associations between
SNPs in the promoter region and TNF-α levels.
Conclusion
In this study, innate cytokine production of TNF-α, IL-1β, IL-6 and IL-10 was not related to
historical disease characteristics or disease severity in patients with quiescent CD. These
findings suggest that genetically determined levels of these cytokines obtained from LPS-
stimulated whole blood cultures are not linked with disease behavior or severity.
Introduction
There is a wide variation in the disease course in patients with Crohn’s Disease (CD) ranging
from mild ileal inflammation to involvement of the entire gastro-intestinal tract with complica-
tions from penetrating disease and extra-intestinal manifestations. So far no reliable biomark-
ers have been identified as tools to predict disease course [1]. Among the studied biomarkers,
patterns in cytokine production remain of particular interest, because of their significant role
in the pathogenesis and course of CD [2–5]. The latter is illustrated by genome wide association
studies showing that many susceptibility loci for CD are involved in the regulation of cytokine
production [6].
The quantity of cytokines produced by individuals after exposure to a stimulus such as lipo-
polysaccharide (LPS) varies to a large extent [7,8]. A persons’ cytokine production appears to
be genetically regulated for 60–70% [9]. This, in combination with a limited intrapersonal vari-
ability makes that individuals can be categorized as high- or low producers [10–13]. Prior
research in other inflammation-driven diseases showed an association between innate cytokine
production and both disease course and response to treatment [14–16].
In CD the defective mucosal barrier of the gut lumen is predominantly exposed to gram-
negative bacteria, containing high levels of LPS. In this way individual differences in cytokine
production might steer the severity of inflammation and predict the disease course of patients
with CD. With this hypothesis previous studies found an association between innate cytokine
production in mucosal tissue and disease behavior. For example, mucosal levels of the pro-
inflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 were
associated with disease relapse [17,18], while lower mucosal levels of the anti-inflammatory IL-
10 increased the risk of disease [19]. However, the feasibility of mucosal cytokine measure-
ments for clinical practice remains limited due to the need for biopsies.
Recent studies with peripheral blood exploring cytokine production of stimulated white
blood cells also showed an association with disease phenotype [20,21]. These data suggest that
individual cytokine production from peripheral blood might be used as biomarker to stratify
patients according to the disease course [1]. An important issue is that most of these studies
included patients with either active disease or patients with maintenance therapy, both are
known to influence the host cytokine production [16,22–25]. By studying patients with CD
currently in remission and not taking immunomodulators or biologicals, we aimed to reduce
confounders that modulate cytokine production. For this reason, we measured LPS-stimulated
cytokine production of TNF-α and other key cytokines (IL-1β, IL-6 and IL-10) in patients with
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quiescent CD, not using immunomodulators or biologicals and correlated these data to disease
characteristics and phenotype to establish their role in disease development.
Methods
Ethics Statement
The local ethics committee, METC Arnhem Nijmegen, the Netherlands, approved the study
under the protocol number 2013/091 and written informed consent was obtained from all par-
ticipating patients. The study complies with the declaration of Helsinki.
Study population
Patients with CD in remission (defined as a Harvey-Bradshaw Index 4) were eligible for par-
ticipation. Patients using non-steroidal anti-inflammatory drugs, biologicals (anti-TNF-α
agents) or immunomodulating drugs (thiopurines, glucocorticoids, methotrexate and cyclo-
sporine) other than 5-aminosalicylic derivates in the past six months were not eligible for study
participation as these drugs modulate ex vivo cytokine production [16,21–24,26–30]. To pre-
vent the formation of a non-representative sample of patients with only mild disease, a history
of CD-related abdominal surgery was set as an additional inclusion criterion. Exclusion criteria
were concomitant systemic diseases, active malignancy or smoking of more than five cigarettes
per day [31]. At the day of inclusion heparinized blood (10 ml) was collected for cytokine mea-
surements together with samples for C-reactive protein (CRP) and hemocytometry (as mea-
sured in the central hospital laboratory). Patients with CRP levels>10 mg/l or leukocyte
counts outside normal limits were excluded for analysis [32]. Age- and sex-matched healthy
controls were included. Patients were enrolled at the Radboud University Medical Center in
Nijmegen, the Netherlands.
Disease phenotype
Medical records were checked prior to cytokine measurements by one investigator (MB) for
the following variables: disease duration, disease behavior according to the Montreal classifica-
tion [33], occurrence of extra- intestinal symptoms, number of bowel resections and the time
frame during which glucocorticoids, thiopurines, biologicals, methotrexate or cyclosporine had
been prescribed. Besides analyses based on phenotypes derived from the Montreal classifica-
tion we compared patients with a combination of ileal disease in the absence of fistulas (classi-
fied as mild disease type) and patients with penetrating disease in combination with activity in
both ileum and colon (classified as severe disease type). Two other outcomes used to separate
mild and severe disease type were number of bowel resections and the percentage of years in
which a patient received systemic treatment (glucocorticoids, thiopurines, methotrexate or bio-
logicals). Both the number of bowel resections as wells as the number of years in which a
patient received systemic treatment were corrected for disease duration to exclude bias by
exposure time.
Cytokine measurement
Cytokines were measured in whole blood cultures after stimulation with E.coli O55:B5 LPS
(Sigma Chemical, St. Louis, USA). Compared to isolated peripheral blood mononuclear cells
(PBMCs), measuring cytokines in a whole blood culture has the advantage of preserving the
physiological proportions of all natural components of the blood [34]. Briefly, heparinized
blood samples (BD Vacutainer, BD, Belliver Industrial Estate, Plymouth, United Kingdom)
were drawn and within one hour of collection 2 ml blood was diluted 1:5 with RPMI 1640
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(RPMI; PAA Laboratories GmbH) supplemented with glutamine. Diluted blood was seeded
into a 6-well microtiter plate and stimulated with 1 ng/ml (final concentration) LPS. Blood was
incubated at 37°C and 5% CO2. Supernatants were harvested after four hours (TNF-α) and 24
hours (other cytokines) of incubation and stored at -80°C until usage [28]. TNF-α levels were
measured using specific Pelikine compactTM human TNF-α enzyme-linked immunosorbent
assay (ELISA) kits (Sanquin, Amsterdam, The Netherlands) according to the manufactures
instructions with a sensitivity of 1–3 pg/ml. IL-1β, IL-6 and IL-10 were measured with specific
Duoset ELISA Development kits (R&D Systems Inc, Minneapolis, MN, USA), with a sensitivity
of 3.91 pg/mL for IL-1β (http://www.rndsystems.com/Products/DY201-05), 9.38 pg/mL for IL-
6, (http://www.rndsystems.com/Products/dy206-05/), and 31.2 pg/ml for IL-10 (http://www.
rndsystems.com/Products/DY217B-05), respectively. Cytokine levels where corrected for total
leukocyte counts.
Polymorphisms in the TNF-α promoter region
The presence of single nucleotide polymorphisms (SNPs) in the promoter region of TNF-α has
been linked to the TNF-α production [12] and is in this way used as a surrogate marker to
explore correlations between TNF-α production and disease characteristics [35]. To test this
assumption in our cohort we correlated SNPs in the promoter region of the TNF-α gene with
TNF-α levels. Herefore, genomic DNA was isolated with the High Pure PCR Template Prepa-
ration Kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturers
protocol. This kit removes heparin from the sample and therewith avoids its influence on the
polymerase chain reaction (PCR). After dividing it into two blocks the TNF-α promoter region
was amplified by PCR using the primers depicted in Table 1. PCR products were analyzed by
Sanger sequencing on an ABI3730 Genetic Analyzer (Applied Biosystems). A combination of
Gene Runner, version 3.00 (Hasting Software, Inc) and ChromasPro, version 1.15 (Technely-
sium Pty Ltd, Australia) was used to screen the TNF-α promoter region for the presence of
SNPs. Analysis were done prior to measurement of TNF-α levels.
Statistics
Depending on the distribution of the data, mean with SD (parametric) or median with IQR
(non-parametric) test were used. The relation between SNPs in the promoter region of the
TNF-α gene and TNF-α production was analyzed using the Kruskal-Wallis test. Haplotypes of
polymorphisms in the TNF-α promoter region seen in more than three patients were tested for
associations with TNF-α production. A two-tailed p-value of<0.05 was considered significant
and Bonferroni correction was used to deal with multiple testing. Statistical analysis was per-
formed by using SPSS version 20.0.0.1 (SPSS Inc, Chicago, IL, USA).
Table 1. Primer sequences and conditions for the TNF-α promoter gene.
Primer Sequence Temperature [Mg]
Block 1 Forward 5’-CTGTGGGGAGAACAAAAGGAT 56°C 2.0 mM
Reverse 5’-GGACCAGGTCTGTGGTCTGT
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Results
Baseline characteristics
In total, 75 patients with histologically confirmed CD were included. Six patients were excluded
for analysis based on elevated CRP levels or leukocyte counts. Baseline characteristics of the
remaining 69 patients and 24 healthy controls are depicted in Table 2. There was no significant
difference in gender (p = 0.97) and age (p = 0.2) between patients and controls.





Female, n (%) 50 (72.5) 18 (75.0)
Age, mean years (SD) 51.2
(12.3)
54.7 (9.5)
Disease duration, mean years (SD) 24.1
(11.5)
-
Age at diagnosis, n (%)
A1 (<17 years) 5 (7.2) -
A2 (17–40 years) 57 (82.6) -
A3 (>40 years) 7 (10.1) -
Disease localization, n (%)
L1 (ileal disease) 33 (47.8) -
L2 (colonic disease) 8 (11.6) -
L3 (ileocolonic) 28 (40.6) -
L4 (Upper GI-tract) 1 (1.4) -
Perianal disease 21 (30.4) -
Prior disease behavior, n (%)
B1 (non stricturing, non ﬁstulating) 14 (20.3) -
B2 (stricturing) 44 (63.8) -
B3 (ﬁstulating) 38 (55.1) -
Current 5-ASA use, n (%) 17 (24.6) 0 (0)
Prior drug history, n (%)
Steroids 62 (89.9) 0 (0)
Thiopurines 37 (53.6) 0 (0)
Biologicals 6 (8.7) 0 (0)
Methotrexate 1 (1.4) 0 (0)
Cyclosporine 2 (2.9) 0 (0)
Prior extra-intestinal manifestations
Arthralgia, n (%) 18 (26.1) -
Number of bowel resections in the past, n (%)
1 48 (69.6) 0 (0)
2 16 (23.2) 0 (0)
 3 5 (7.2) 0 (0)
Mild versus severe disease, n (%)
Mild disease (L1 without history of ﬁstulas) 27 (39.1) -
Severe disease (L3 with history of ﬁstulas)their disease course we are not afraid
that this might inﬂuence
16 (23.2) -
CD, Crohn’s disease; HC, healthy controls; SD, standard deviation; 5-ASA, 5-aminosalicylic acid.
doi:10.1371/journal.pone.0133932.t002
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Healthy controls versus patients with quiescent CD
Patients with CD had significant higher TNF-α levels upon stimulation with LPS (p = 0.02).
No difference was seen with IL-1β, IL-6 and IL-10 between patients with CD and healthy con-
trols (Table 3).
Correlation between cytokine production and disease phenotypes. Table 4 and Fig 1
show the median cytokine production and corresponding p-values in relation to disease char-
acteristics and disease severity. None of the disease characteristics showed a significant correla-
tion with TNF-α, IL-1β, IL-6 or IL-10 levels.
Polymorphisms in the TNF-α promoter region and TNF-α production
Fig 2 shows the TNF-α values of patients with various genotypes in the TNF-α promoter
region. We found no evidence for an increased TNF-α production in LPS-stimulated whole
blood cultures of patients with one or more SNPs in the TNF-α promoter region. The -308A
genotype, the most used surrogate marker for a high producer phenotype, showed a median
[IQR] TNF-α production of 450 pg/ml [306–554] compared to 469 pg/ml [378–590] in
Table 3. cytokine production in healthy controls versus patients with quiescent CD.
Healthy controls (n = 24) CD (n = 69) P value
TNF-α [IQR] 428 [267–468] 459 [364–570] 0.02
IL-1β [IQR] 679 [565–878] 561 [374–850] 0.11
IL-6 [IQR] 2687 [1830–3228] 2384 [1703–3049] 0.39
IL-10 [IQR] 80 [61–149] 82 [59–107] 0.52
Cytokine levels (pg/ml) are presented as medians with the interquartile range [IQR]. TNF-α, Tumor necrosis
factor alpha; IL, Interleukin; IQR, interquartile range; CD, Crohn's disease.
doi:10.1371/journal.pone.0133932.t003
Table 4. Cytokine production and disease characteristics.
TNF-α [IQR] P value IL-1β [IQR] P value IL-6 [IQR] P value IL-10 [IQR] P value
HC (n = 24) 428 [267–468] 679 [565–878] 2687 [1830–3228] 80 [61–149]
Localization
L1 (n = 33) 454 [362–624] 561 [356–903] 2384 [1585–3017] 89 [65–107]
L2 (n = 8) 516 [469–560] 603 [237–1243] 2715 [1701–3465] 64 [30–83]
L3 (n = 28) 421 [354–561] 0.41 568 [387–750] 0.90 2395 [1756–2830] 0.79 81 [55–112] 0.22
P—(n = 48) 452 [368–573] 569 [380–901] 2384 [1711–2872] 88 [64–111]
P + (n = 21) 483 [325–575] 0.98 560 [272–747] 0.58 2491 [1469–3332] 0.92 75 [55–107] 0.32
Behavior
No ﬁstulas (n = 31) 454 [400–563] 561 [384–905] 2417 [1707–2816] 79 [55–107]
Fistulas (n = 38) 462 [350–579] 0.55 568 [298–813] 0.62 2351 [1567–3305] 0.81 82 [62–108] 0.50
No strictures (= 25) 408 [351–584] 511 [254–859] 2402 [1691–3062] 90 [67–114]
Strictures (n = 44) 476 [387–573] 0.38 569 [400–866] 0.45 2384 [1703–3049] 0.92 77 [54–107] 0.12
Extra intestinal manifestations
No arthralgia (n = 51) 454 [373–578] 577 [379–902] 2445 [1706–3045] 85 [62–106]
Arthralgia (n = 18) 476 [348–562] 0.90 550 [261–796] 0.51 2204 [1588–3088] 0.46 82 [53–124] 0.77
Cytokine levels (pg/ml) are presented as medians with the interquartile range [IQR]. HC, Healthy control; TNF-α, Tumor necrosis factor alpha; IL,
Interleukin; L1, ileal disease; L2, colonic disease; L3, ileocolonic disease; P-, no peri-anal disease; P+, peri-anal disease; IQR, interquartile range.
doi:10.1371/journal.pone.0133932.t004
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patients with the most common genotype (P = 0.25). The -863AA genotype (TNF-α produc-
tion of 523 pg/ml) and -857TT genotype (TNF-α production of 1053 pg/ml) were only detected
once and were not included in Fig 2. The haplotypes, -1032T with -863A (n = 12), and -1032T
with -238A (n = 4) were not related with TNF-α production.
Discussion
We found that the inter individual variation in LPS-induced production of TNF-α, IL-1β, IL-6
and IL-10 in whole blood cultures was not related to disease phenotype in patients with quies-
cent CD who were not taking immunomodulators or biologicals. Also, when disease character-
istics where combined to differentiate mild from more severe disease type no differences were
found.
The innate cytokine production by an individual is constant over time, but might be affected
by many variables such as disease activity and concomitant drug treatment [16,22–29,31,36].
For this reason we excluded patients with disease activity or maintenance therapy, thereby
minimizing variables other than genetic that can modulate cytokine production as far as possi-
ble. To our knowledge, only a limited number of studies included patients with CD in remis-
sion without maintenance therapy [5,21,37]. In these studies decreased levels of TNF-α and
Fig 1. Relation between cytokine production and disease severity. Values are presented as medians
(pg/ml) with the interquartile range. For the number of bowel resections and treatment exposure patients were
dichotomized in a low and high group according to the number of resections or the percentage of years in
which they were treated with steroids, thiopurines, biologicals, methotrexate or cyclosporine, corrected for
disease duration. Two patients were excluded for the analysis for treatment exposure, because no complete
drug history was available. TNF-α, Tumor necrosis factor alpha; IL, Interleukin; L1, ileal disease; L3,
ileocolonic disease; P-, no fistulas; P+, fistulating disease.
doi:10.1371/journal.pone.0133932.g001
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IL-6 produced by monocyte derived macrophages compared to healthy controls were found.
Furthermore, an association with disease localisation in patients with CD was seen e.g. patients
with colonic disease (L2) had significant lower TNF-α production upon LPS stimulation com-
pared to patients with only ileal disease (L1) [21]. We did not find a significant difference in
cytokine production between patients with L1 and L2 disease in our study. A possible explana-
tion here might be that in our cohort only a small number of patients (n = 8; 11.6%) had
exclusively colonic disease, compared to 44 (43.6%) in the study of Sewell et al. [21] Another
explanation might be that they studied cytokine production from monocyte-derived macro-
phages, while we studied whole blood cultures. To our knowledge there are no studies compar-
ing cytokine production of whole blood cultures (including all natural components) with a
homogeneous cell suspension of monocyte-derived macrophages, which makes it difficult to
interpret these differences. It is unlikely that the higher TNF-α levels which we found in
patients with CD were caused by disease activity, but this cannot completely be excluded. A
more likely explanation can be found in the different cell populations being investigated. The
presence of neutrophils in a whole blood culture is the most important difference in experi-
mental setup compared to stimulation of isolated peripheral monocytes or monocyte derived
macrophages. Since TNF-α production is equal in isolated peripheral monocytes in CD and
healthy controls [38], it might be that an impaired inhibitory function by neutrophils on pro-
inflammatory cytokine production led to higher TNF-α values in patients with CD [39]. A
recent study indeed showed a disturbed cell signaling in neutrophils from patients with CD,
which supports our hypothesis [40]. However, further research is warranted to elucidate this
mechanism.
Fig 2. TNF-α production (pg/ml) according to (SNPs) in the promoter region of the TNF-α gene. Values
are expressed as medians with the interquartile range. The median value of the healthy controls serves as
reference. TNF-α, Tumor necrosis factor alpha; SNPs, single nucleotide polymorphisms
doi:10.1371/journal.pone.0133932.g002
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With respect to IL-6, there is another study which also used LPS stimulated whole blood
cultures and measured IL-6 levels in patients with CD and HD. They found reduced IL-6 levels
in patients with CD, however this study included patients with active disease and on mainte-
nance therapy [41]. This might have influenced IL-6 levels and such makes it hard to compare
with our results.
IL-10 is considered the most potent anti-inflammatory cytokine in the human immune
response, playing a key role in immune homeostasis. Its significance for CD follows from IL-10
knock-out mice developing CD-like enterocolitis [42]. Furthermore, SNPs in IL-10 may predis-
pose for young onset CD, which is considered as more severe and difficult to treat [43]. There-
fore, it can be hypothesized that patients with a high producer phenotype of IL-10 have a
milder disease course [19]. A study in patients with CD in remission showed that IL-10 levels
were decreased in patients with a history of fistulating disease [44]. An important difference
with our study is that the majority of the patients in the latter study used immunomodulators.
Since fistulas are more difficult to treat, it is likely that especially these patients were on immu-
nosuppressive medication. Knowing that immunomodulating agents affect cytokine produc-
tion, this might have influenced their findings [23].
Techniques of measuring cytokine production in peripheral blood have been well estab-
lished. However, apart from studies comparing cytokine levels of healthy persons with patients
with CD, the application of these techniques to explore a relation with disease characteristics in
CD is limited to a few recent studies [20,21,44]. An alternative strategy to categorize patients as
high- or low producers is to look at SNPs involved in cytokine regulation. These SNPs can lead
to an increase or decrease in cytokine production and their presence is therefore used as a
surrogate marker for high- or low producer phenotype [35,45]. Our study was not primarily
designed to explore an association between SNPs in the TNF-α gene and TNF-α production.
Even so the results do not support such a relation, which is in line with recent literature [46].
Therefore, it seems more appropriate to categorize patients as being low or high producer
based on actual cytokine measurements rather than on genetic proxy’s.
Our study comes with some limitations. First of all, the power of our study to pick up more
subtle associations can be compromised by our strict inclusion criteria, which limited the num-
ber of enrolled patients. Nevertheless, the included patients represent a unique population of
patients with CD in whom immune functions are probably not disturbed by disease activity or
concomitant use of immunomodulating drugs. Furthermore, we defined “remission” as a Har-
vey-Bradshaw Index of 4, in combination with normal leukocyte counts and CRP levels.
Although colonoscopy is the golden standard to exclude mucosal inflammation, this was con-
sidered a too high burden for our patients in this setting. The strict inclusion criteria precluded
participation of patients with maintenance therapy or active disease, i.e. those with a potentially
severe disease course. However, compared to a previous study in patients with CD in our hos-
pital no differences were seen in disease characteristics [47], suggesting that our inclusion crite-
ria did not lead to significant selection bias. Differences in the moment of diagnosis may have
influenced the outcomes for drug exposure to some extent, because of evolving treatment
regimes. More specifically, patients with a longer disease history were relatively underexposed
to new treatment modalities, while patients with a more recent date of diagnosis usually are
confronted with steroid-free treatment strategies. To prevent bias, we merged the data of gluco-
corticoid, thiopurine, biological and other immunosuppressants use. This gave us a valuable
impression for the need of immunnosupressive drugs to control disease activity. In order to
prevent bias, medical records and presence of SNPs in the TNF-α promoter region were ana-
lyzed before measuring TNF-α production.
In conclusion, in this study TNF-α, IL-1β, IL-6 and IL-10 production in LPS-stimulated
whole blood cultures of patients with CD in remission and without taking immunomodulating
Innate Cytokine Production and Crohn's Disease
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drugs or biologicals could not be correlated to historical disease phenotype, course or severity.
This suggests that individual differences in innate cytokine production are not important for
the development of disease phenotype in CD.
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